Johnson & Johnson (NYSE:JNJ) Shares Sold by First National Bank of Omaha

First National Bank of Omaha decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,280 shares of the company’s stock after selling 5,815 shares during the quarter. Johnson & Johnson makes up 0.8% of First National Bank of Omaha’s investment portfolio, making the stock its 28th biggest holding. First National Bank of Omaha’s holdings in Johnson & Johnson were worth $12,200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Dunhill Financial LLC increased its stake in shares of Johnson & Johnson by 11.6% during the third quarter. Dunhill Financial LLC now owns 3,142 shares of the company’s stock worth $509,000 after buying an additional 327 shares during the period. Bontempo Ohly Capital Mgmt LLC grew its holdings in Johnson & Johnson by 6.5% during the 3rd quarter. Bontempo Ohly Capital Mgmt LLC now owns 15,601 shares of the company’s stock worth $2,528,000 after acquiring an additional 951 shares in the last quarter. Delos Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 58.6% in the 3rd quarter. Delos Wealth Advisors LLC now owns 2,450 shares of the company’s stock valued at $397,000 after purchasing an additional 905 shares in the last quarter. Orion Portfolio Solutions LLC lifted its position in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 201,788 shares of the company’s stock worth $32,702,000 after purchasing an additional 5,562 shares during the last quarter. Finally, World Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 678.8% during the third quarter. World Investment Advisors LLC now owns 222,536 shares of the company’s stock worth $36,064,000 after purchasing an additional 193,962 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

NYSE:JNJ opened at $149.31 on Friday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock’s 50 day simple moving average is $158.09 and its 200-day simple moving average is $156.38. The firm has a market cap of $359.48 billion, a P/E ratio of 21.61, a PEG ratio of 2.67 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter in the prior year, the firm earned $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several analyst reports. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Citigroup increased their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.